Sunflower Pharmaceutical Group Co., Ltd.
Kuihua Pharmaceutical Group Co., Ltd. is based on the mission of "guaranteeing the safety of Chinese children's medication, protecting the healthy growth of Chinese children. Being a good medicine for the people and bringing a healthy and beautiful life to hundreds of millions of families". It has a brand OTC product as the core and covers R&D. , well-known pharmaceutical companies in the entire industrial chain. The group was formerly the former state-owned Wuchang Pharmaceutical Factory in Heilongjiang Province. In 1998, it was reorganized into a private enterprise, Heilongjiang Kuihua Pharmaceutical Co., Ltd., and then continued to grow and grew. In 2005, Kuihua Pharmaceutical Group Co., Ltd. was established. The group currently has 32 subsidiaries including 13 pharmaceutical production enterprises, 6 sales companies, 4 pharmaceutical research institutes, 2 medicinal materials planting bases, and 1 pharmaceutical packaging company. It is headquartered in Harbin City. Listed in Shenzhen at the end of 2014, with stock code: 002737. The company is currently the executive vice president unit of the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce, the vice president unit of the China Pharmaceutical Enterprise Management Association, the vice president unit of the China Pharmaceutical Business Association, the member unit of the China Traditional Chinese Medicine Association, and the vice president of the Chronic Disease Professional Committee of the China Traditional Chinese Medicine Association Unit, senior vice president unit of China Over-the-counter Drug Association, etc. Kuihua Pharmaceutical Group is dominated by traditional Chinese medicine, with "chemical drugs, biological drugs" and "healthy and health products" as its two wings, and is in the six major fields of "pediatrics, gynecology, digestive system, respiratory colds, rheumatism and bone diseases, and cardiovascular and cerebrovascular diseases". It has formed a comprehensive layout of product pipelines and has a rich product line, with a total of 21 dosage forms, 257 products in production, and 1,126 drug approval numbers. Among them, nearly 100 children's medicine approval numbers have been held and more than 60 sold drug products. Xiao Kuihua Children's Medicine has unshakable advantages in the same category in the OTC field in terms of "sales scale, product quantity, and scale single products". . The company is an OTC large-scale enterprise with "dual brand umbrellas". "Sunflower" and "Little Sunflower" have built the consumer trust foundation for the company's adult medicine and children's medicine. After more than 20 years of creation, the company has adopted the combination marketing model of "brand model, general medicine model, prescription model, big health model, new retail model" and other combination marketing models to build a unique combination marketing and full model in the industry. The integration model has attracted attention and imitation in the industry.
Sunflower Pharmaceutical Group Co., Ltd.
Kuihua Pharmaceutical Group Co., Ltd. is based on the mission of "guaranteeing the safety of Chinese children's medication, protecting the healthy growth of Chinese children. Being a good medicine for the people and bringing a healthy and beautiful life to hundreds of millions of families". It has a brand OTC product as the core and covers R&D. , well-known pharmaceutical companies in the entire industrial chain. The group was formerly the former state-owned Wuchang Pharmaceutical Factory in Heilongjiang Province. In 1998, it was reorganized into a private enterprise, Heilongjiang Kuihua Pharmaceutical Co., Ltd., and then continued to grow and grew. In 2005, Kuihua Pharmaceutical Group Co., Ltd. was established. The group currently has 32 subsidiaries including 13 pharmaceutical production enterprises, 6 sales companies, 4 pharmaceutical research institutes, 2 medicinal materials planting bases, and 1 pharmaceutical packaging company. It is headquartered in Harbin City. Listed in Shenzhen at the end of 2014, with stock code: 002737. The company is currently the executive vice president unit of the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce, the vice president unit of the China Pharmaceutical Enterprise Management Association, the vice president unit of the China Pharmaceutical Business Association, the member unit of the China Traditional Chinese Medicine Association, and the vice president of the Chronic Disease Professional Committee of the China Traditional Chinese Medicine Association Unit, senior vice president unit of China Over-the-counter Drug Association, etc. Kuihua Pharmaceutical Group is dominated by traditional Chinese medicine, with "chemical drugs, biological drugs" and "healthy and health products" as its two wings, and is in the six major fields of "pediatrics, gynecology, digestive system, respiratory colds, rheumatism and bone diseases, and cardiovascular and cerebrovascular diseases". It has formed a comprehensive layout of product pipelines and has a rich product line, with a total of 21 dosage forms, 257 products in production, and 1,126 drug approval numbers. Among them, nearly 100 children's medicine approval numbers have been held and more than 60 sold drug products. Xiao Kuihua Children's Medicine has unshakable advantages in the same category in the OTC field in terms of "sales scale, product quantity, and scale single products". . The company is an OTC large-scale enterprise with "dual brand umbrellas". "Sunflower" and "Little Sunflower" have built the consumer trust foundation for the company's adult medicine and children's medicine. After more than 20 years of creation, the company has adopted the combination marketing model of "brand model, general medicine model, prescription model, big health model, new retail model" and other combination marketing models to build a unique combination marketing and full model in the industry. The integration model has attracted attention and imitation in the industry.
Chengdu Enwei Investment (Group) Co., Ltd.
Founded in 1986, Chengdu Enwei Group is a high-tech multinational enterprise integrating scientific research, production and trade, led by the technology industry expert Xue Yongxin, and led by Enwei people to work hard and work hard to manage. The group has more than 10 subsidiaries and 27 offices. It has a total of tens of billions of assets. The group's main body, Sichuan Enwei Pharmaceutical Co., Ltd., has registered capital of more than 110 million yuan, and currently has more than 3,000 employees, including 32 doctoral, postdoctoral, and senior engineers. Bachelor degree or above accounts for 58% of the total number of employees. It is a national designated postdoctoral fellow Mobile station. Benefit and power are "water", "benefit all things without fighting." The philosophical thoughts of Tao, Buddhism and Confucianism as the guide, established the corporate philosophy of "Wishing all living beings to be happy and social auspicious", "Serving society and benefiting mankind" as the corporate purpose, and Taoism The "inaction" idea is the corporate spirit, and it uses it to guide the business of the enterprise. In order to "save the world and benefit all living beings", Enwei chose the traditional Chinese medicine industry, combining the traditional Chinese medicine with 5,000 years of history with Chinese culture and modern medical technology, and establishing a Chinese-style and Chinese characteristics around life sciences. The pharmaceutical industry is to relieve the pain and troubles brought to human body and mind by modern diseases. For more than 20 years, Enwei Group has always adhered to its beliefs and purpose, experienced difficulties and twists and turns, and ushered in today's glory. Enwei Group has always adhered to market-oriented and consumer satisfaction as the core, established a commercial network of consumers → pharmacies → secondary dealers → first-level dealers → group headquarters, and established sales staff, The medical staff network, from pharmacies to patients, establishes family health records, performs the duties of a family physician, and serves patients. Enwei Group uses modern information and network technology to integrate the Internet and the group's local area network. Through the CRM system, it implements online reporting, approval, and all patient information, health consultation, commercial orders, salesperson market trends, plans, and expenses. Review. All information is collected into the group company through the Internet for the group to study and formulate scientific research, production and business strategies. Enwei Group closely combines corporate beliefs and market demand, formulates an industrial strategy for harmonious development between man and nature, invests in and establishes three pharmaceutical bases and packaging bases in Chengdu Hi-Tech Zone, Shuangliu and Haikou City, Hainan Province, and establishes in Sichuan Province. Three Chinese herbal medicine planting bases. Among them, according to the requirements of GAP, nearly 10,000 mu of precious Chinese medicinal materials bases are invested and built, and nearly 50,000 mu of the company's raw materials planting bases are invested and built, effectively ensuring the quantity and quality of raw materials. In order to serve the new drugs independently developed to all living beings, the group company introduced professional instruments and equipment from Europe and the United States, and made traditional Chinese medicine into dosage forms without adding any auxiliary materials during the production process to ensure the natural purity and quality of the drugs produced. At the same time, the company has integrated ISO9000 quality management system and GMP pharmaceutical specifications into production management since the early 1990s, and passed the certification to effectively ensure that product quality always maintains a high level with a scientific and standardized quality and production process management system. .
Chengdu Enwei Investment (Group) Co., Ltd.
Founded in 1986, Chengdu Enwei Group is a high-tech multinational enterprise integrating scientific research, production and trade, led by the technology industry expert Xue Yongxin, and led by Enwei people to work hard and work hard to manage. The group has more than 10 subsidiaries and 27 offices. It has a total of tens of billions of assets. The group's main body, Sichuan Enwei Pharmaceutical Co., Ltd., has registered capital of more than 110 million yuan, and currently has more than 3,000 employees, including 32 doctoral, postdoctoral, and senior engineers. Bachelor degree or above accounts for 58% of the total number of employees. It is a national designated postdoctoral fellow Mobile station. Benefit and power are "water", "benefit all things without fighting." The philosophical thoughts of Tao, Buddhism and Confucianism as the guide, established the corporate philosophy of "Wishing all living beings to be happy and social auspicious", "Serving society and benefiting mankind" as the corporate purpose, and Taoism The "inaction" idea is the corporate spirit, and it uses it to guide the business of the enterprise. In order to "save the world and benefit all living beings", Enwei chose the traditional Chinese medicine industry, combining the traditional Chinese medicine with 5,000 years of history with Chinese culture and modern medical technology, and establishing a Chinese-style and Chinese characteristics around life sciences. The pharmaceutical industry is to relieve the pain and troubles brought to human body and mind by modern diseases. For more than 20 years, Enwei Group has always adhered to its beliefs and purpose, experienced difficulties and twists and turns, and ushered in today's glory. Enwei Group has always adhered to market-oriented and consumer satisfaction as the core, established a commercial network of consumers → pharmacies → secondary dealers → first-level dealers → group headquarters, and established sales staff, The medical staff network, from pharmacies to patients, establishes family health records, performs the duties of a family physician, and serves patients. Enwei Group uses modern information and network technology to integrate the Internet and the group's local area network. Through the CRM system, it implements online reporting, approval, and all patient information, health consultation, commercial orders, salesperson market trends, plans, and expenses. Review. All information is collected into the group company through the Internet for the group to study and formulate scientific research, production and business strategies. Enwei Group closely combines corporate beliefs and market demand, formulates an industrial strategy for harmonious development between man and nature, invests in and establishes three pharmaceutical bases and packaging bases in Chengdu Hi-Tech Zone, Shuangliu and Haikou City, Hainan Province, and establishes in Sichuan Province. Three Chinese herbal medicine planting bases. Among them, according to the requirements of GAP, nearly 10,000 mu of precious Chinese medicinal materials bases are invested and built, and nearly 50,000 mu of the company's raw materials planting bases are invested and built, effectively ensuring the quantity and quality of raw materials. In order to serve the new drugs independently developed to all living beings, the group company introduced professional instruments and equipment from Europe and the United States, and made traditional Chinese medicine into dosage forms without adding any auxiliary materials during the production process to ensure the natural purity and quality of the drugs produced. At the same time, the company has integrated ISO9000 quality management system and GMP pharmaceutical specifications into production management since the early 1990s, and passed the certification to effectively ensure that product quality always maintains a high level with a scientific and standardized quality and production process management system. .
Northeast Pharmaceutical Group Co., Ltd.
Northeast Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Northeast Pharmaceutical", stock code: 000597) is a listed company under Liaoning Fangda Group Industrial Co., Ltd. (hereinafter referred to as "Fangda Group"). The company was formerly the Northeast Pharmaceutical General Factory. It was founded in 1946. It has assisted in the construction of 52 pharmaceutical enterprises in 19 provinces and cities across the country, and has transported more than 1,300 cadres to the outside world. It is known as the cradle of my country's national pharmaceutical industry. At present, Northeast Pharmaceutical has major business segments such as chemical raw materials, chemical preparations, pharmaceutical commerce, pharmaceutical engineering, and biomedicine, covering the entire industrial chain of pharmaceutical research and development, manufacturing, and distribution. It has an employee team of more than 8,500 people and a total assets of 12 billion yuan. The company mainly produces vitamin series drugs, anti-infection system drugs, obstetrics and gynecology system drugs, digestive system drugs, urinary system drugs, antiviral series drugs, cardiovascular and cerebrovascular series drugs, analgesic and cough-relieving series drugs, biological diagnosis series, big health There are ten series of fine products including the field series, as well as more than 400 chemical raw materials, pharmaceutical intermediates and preparation products. The leading products are exported to more than 100 countries and regions. The company has a strong product manufacturing system. The preparation production base covers an area of 180,000 square meters, has more than 30 production lines, and an annual production capacity of 10 billion pieces (branches, pills, pellets, pellets, and bottles). The raw materials production base covers an area of 910,000 square meters. It is a national intelligent manufacturing demonstration factory for bulk raw materials and pharmaceutical intermediates. Its main products include vitamin C and series, L-carnitine series, Fosfomycin series, piracetam, and Kaprinline. Methyl esters, adamantine, sulfaluminum, berberine, chloramphenicol, etc. are fully extended to the downstream Northeast pharmaceutical preparation industry chain, forming a comprehensive competitive advantage that is difficult to replicate. The company has a national advanced environmental protection treatment system to achieve all-round treatment of sewage, exhaust gas, noise and solid waste. The treatment capacity of the raw materials and drug sewage treatment system reaches 50,000 cubic meters per day. The incinerator can handle 9,000 tons of hazardous waste throughout the year, and exhaust emissions meet EU standards. The circular economy industrial park realizes resource processing of production waste and turns waste into treasure. Northeast Pharmaceuticals has a complete quality management system, and its product quality complies with the new GMP, EP, USP, JP, BP, CP and other quality standards. Many products have successively passed international certifications such as EDQM, FDA, Japan Ministry of Health and Welfare, BRC, HALAL, KOSHER, etc. The leading products have passed the registration and quality audits in many countries and regions such as the United States, Europe, Japan, Brazil, Russia, and Poland. Northeast Pharmaceutical is not only an important drug production and export base in China, but also has independent business companies such as drug research institutes, engineering design companies, equipment manufacturing and installation companies, international trading companies, metrology and testing companies, and hazardous chemical transportation companies, including 5. Our family is a high-tech enterprise. The Northeast Pharmaceutical and Pharmaceutical Business Network covers all prefecture-level cities and counties in Liaoning and extends to the three northeastern provinces. The Northeast Pharmacy has more than 100 chain stores, and the pharmaceutical e-commerce business has achieved online and offline integration, and business model innovation continues to be promoted.
Northeast Pharmaceutical Group Co., Ltd.
Northeast Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Northeast Pharmaceutical", stock code: 000597) is a listed company under Liaoning Fangda Group Industrial Co., Ltd. (hereinafter referred to as "Fangda Group"). The company was formerly the Northeast Pharmaceutical General Factory. It was founded in 1946. It has assisted in the construction of 52 pharmaceutical enterprises in 19 provinces and cities across the country, and has transported more than 1,300 cadres to the outside world. It is known as the cradle of my country's national pharmaceutical industry. At present, Northeast Pharmaceutical has major business segments such as chemical raw materials, chemical preparations, pharmaceutical commerce, pharmaceutical engineering, and biomedicine, covering the entire industrial chain of pharmaceutical research and development, manufacturing, and distribution. It has an employee team of more than 8,500 people and a total assets of 12 billion yuan. The company mainly produces vitamin series drugs, anti-infection system drugs, obstetrics and gynecology system drugs, digestive system drugs, urinary system drugs, antiviral series drugs, cardiovascular and cerebrovascular series drugs, analgesic and cough-relieving series drugs, biological diagnosis series, big health There are ten series of fine products including the field series, as well as more than 400 chemical raw materials, pharmaceutical intermediates and preparation products. The leading products are exported to more than 100 countries and regions. The company has a strong product manufacturing system. The preparation production base covers an area of 180,000 square meters, has more than 30 production lines, and an annual production capacity of 10 billion pieces (branches, pills, pellets, pellets, and bottles). The raw materials production base covers an area of 910,000 square meters. It is a national intelligent manufacturing demonstration factory for bulk raw materials and pharmaceutical intermediates. Its main products include vitamin C and series, L-carnitine series, Fosfomycin series, piracetam, and Kaprinline. Methyl esters, adamantine, sulfaluminum, berberine, chloramphenicol, etc. are fully extended to the downstream Northeast pharmaceutical preparation industry chain, forming a comprehensive competitive advantage that is difficult to replicate. The company has a national advanced environmental protection treatment system to achieve all-round treatment of sewage, exhaust gas, noise and solid waste. The treatment capacity of the raw materials and drug sewage treatment system reaches 50,000 cubic meters per day. The incinerator can handle 9,000 tons of hazardous waste throughout the year, and exhaust emissions meet EU standards. The circular economy industrial park realizes resource processing of production waste and turns waste into treasure. Northeast Pharmaceuticals has a complete quality management system, and its product quality complies with the new GMP, EP, USP, JP, BP, CP and other quality standards. Many products have successively passed international certifications such as EDQM, FDA, Japan Ministry of Health and Welfare, BRC, HALAL, KOSHER, etc. The leading products have passed the registration and quality audits in many countries and regions such as the United States, Europe, Japan, Brazil, Russia, and Poland. Northeast Pharmaceutical is not only an important drug production and export base in China, but also has independent business companies such as drug research institutes, engineering design companies, equipment manufacturing and installation companies, international trading companies, metrology and testing companies, and hazardous chemical transportation companies, including 5. Our family is a high-tech enterprise. The Northeast Pharmaceutical and Pharmaceutical Business Network covers all prefecture-level cities and counties in Liaoning and extends to the three northeastern provinces. The Northeast Pharmacy has more than 100 chain stores, and the pharmaceutical e-commerce business has achieved online and offline integration, and business model innovation continues to be promoted.
Beijing Kangbide Pharmaceutical Co., Ltd.
Beijing Kangbide Pharmaceutical Co., Ltd. is a large pharmaceutical enterprise located in the Daxing Biopharma Industry Base of Zhongguancun Science and Technology Park in Beijing. It covers an area of 176 acres, adjacent to the Sixth Ring Road and the Beijing-Kai Expressway. It has convenient transportation and beautiful environment. It is a high-tech technology in Beijing. enterprise. Beijing Kangbide Pharmaceutical is committed to the research of green natural medicines, and strives to explore the cultivation of Chinese medicinal materials, the extraction of Chinese medicinal materials, and the refining of Chinese patent medicines, and the development of modern Chinese medicines. The company has built a Ginkgo GAP planting base of 10,000 mu, and has a modern extraction workshop for Chinese herbal medicines treated annually. It uses fingerprint maps, supercritical extraction, macroporous resin, ultrafine crushing and other modern Chinese medicine production technologies, and uses dynamic countercurrent extraction and spraying of Chinese medicines. Advanced process equipment such as drying, and the application of automated control technology has realized the modernization of traditional Chinese medicine production. The preparation workshop has all passed the national GMP certification and can produce more than 100 varieties of 6 dosage forms: tablets, capsules (including hormones), granules, tea agents, oral solutions, syrups, and external solutions. Among them, Fufuchun brand medroxyprogesterone acetate compound capsules, Kangbide brand compound golden lotus granules, glucosamine hydrochloride capsules (Polid), and Yibianshuang brand compound chlorhexidine acetate spray. The company has independent intellectual property rights. The company adheres to the lofty mission of creating life sciences and serving human health, adheres to the corporate spirit of innovation, pragmatism, competition and development, spreads the concept of your health and happiness in life, and takes technological independence, product diversification, market networking, Service the development path of branding and modern management, respect knowledge, respect talents, pay attention to quality, and operate with integrity and law. The company will aim to improve the modern enterprise system, spread health culture, guide health science, create health products, build health brands, be committed to the health cause, and achieve health dreams.
Beijing Kangbide Pharmaceutical Co., Ltd.
Beijing Kangbide Pharmaceutical Co., Ltd. is a large pharmaceutical enterprise located in the Daxing Biopharma Industry Base of Zhongguancun Science and Technology Park in Beijing. It covers an area of 176 acres, adjacent to the Sixth Ring Road and the Beijing-Kai Expressway. It has convenient transportation and beautiful environment. It is a high-tech technology in Beijing. enterprise. Beijing Kangbide Pharmaceutical is committed to the research of green natural medicines, and strives to explore the cultivation of Chinese medicinal materials, the extraction of Chinese medicinal materials, and the refining of Chinese patent medicines, and the development of modern Chinese medicines. The company has built a Ginkgo GAP planting base of 10,000 mu, and has a modern extraction workshop for Chinese herbal medicines treated annually. It uses fingerprint maps, supercritical extraction, macroporous resin, ultrafine crushing and other modern Chinese medicine production technologies, and uses dynamic countercurrent extraction and spraying of Chinese medicines. Advanced process equipment such as drying, and the application of automated control technology has realized the modernization of traditional Chinese medicine production. The preparation workshop has all passed the national GMP certification and can produce more than 100 varieties of 6 dosage forms: tablets, capsules (including hormones), granules, tea agents, oral solutions, syrups, and external solutions. Among them, Fufuchun brand medroxyprogesterone acetate compound capsules, Kangbide brand compound golden lotus granules, glucosamine hydrochloride capsules (Polid), and Yibianshuang brand compound chlorhexidine acetate spray. The company has independent intellectual property rights. The company adheres to the lofty mission of creating life sciences and serving human health, adheres to the corporate spirit of innovation, pragmatism, competition and development, spreads the concept of your health and happiness in life, and takes technological independence, product diversification, market networking, Service the development path of branding and modern management, respect knowledge, respect talents, pay attention to quality, and operate with integrity and law. The company will aim to improve the modern enterprise system, spread health culture, guide health science, create health products, build health brands, be committed to the health cause, and achieve health dreams.
Shanxi Huangchengxiangfu Pharmaceutical Co., Ltd.
Shanxi Huangcheng Xiangfu Pharmaceutical Co., Ltd. is affiliated to Huangcheng Xiangfu Group. It is a high-tech and comprehensive New Third Board listed enterprise integrating production, sales, research and development and operation. Located in Jincheng Economic and Technological Development Zone, covering an area of more than 60,000 square meters, it has a production series of solid preparations, raw material synthesis, traditional Chinese medicine pretreatment and extraction, oral instant film agent, health food, medicinal tea and mineral pure water, etc. It can simultaneously carry out high-intelligent production lines of tablets, capsules, granules, dry suspensions, Chinese medicine extraction, raw material synthesis, and oral instant film agents. The annual production of solid preparations is 3 billion tablets per pill, 1,000 kg of raw materials, 1,000 tons of traditional Chinese medicine extracted, and 300 million tablets of oral instant film agent. The company currently has 450 employees, more than 20 scientific research and development expert team, nearly 80 quality and technology backbone, and more than 50 sales elite team, including more than 80 bachelor's degree, about 100 pharmacy, and nearly 30 practicing pharmacists. The company has established a technical R&D center that meets provincial standards and is a well-known doctoral workstation in Jincheng City. In recent years, technology exchanges and cooperation have been carried out mainly with the technology center as a carrier. In terms of new product development, we insist on independent research and development, create patented products, improve development level, and promote industrial upgrading. Up to now, a total of 6 national patents of various types have been applied for. There are two branches below: Pharmaceutical Branch and Food Branch. Two new subsidiaries were established: Huangcheng Xiangfu Chain Pharmacy Subsidiary Company and Huangcheng Xiangfu Qinhe Pharmaceutical Co., Ltd.
Shanxi Huangchengxiangfu Pharmaceutical Co., Ltd.
Shanxi Huangcheng Xiangfu Pharmaceutical Co., Ltd. is affiliated to Huangcheng Xiangfu Group. It is a high-tech and comprehensive New Third Board listed enterprise integrating production, sales, research and development and operation. Located in Jincheng Economic and Technological Development Zone, covering an area of more than 60,000 square meters, it has a production series of solid preparations, raw material synthesis, traditional Chinese medicine pretreatment and extraction, oral instant film agent, health food, medicinal tea and mineral pure water, etc. It can simultaneously carry out high-intelligent production lines of tablets, capsules, granules, dry suspensions, Chinese medicine extraction, raw material synthesis, and oral instant film agents. The annual production of solid preparations is 3 billion tablets per pill, 1,000 kg of raw materials, 1,000 tons of traditional Chinese medicine extracted, and 300 million tablets of oral instant film agent. The company currently has 450 employees, more than 20 scientific research and development expert team, nearly 80 quality and technology backbone, and more than 50 sales elite team, including more than 80 bachelor's degree, about 100 pharmacy, and nearly 30 practicing pharmacists. The company has established a technical R&D center that meets provincial standards and is a well-known doctoral workstation in Jincheng City. In recent years, technology exchanges and cooperation have been carried out mainly with the technology center as a carrier. In terms of new product development, we insist on independent research and development, create patented products, improve development level, and promote industrial upgrading. Up to now, a total of 6 national patents of various types have been applied for. There are two branches below: Pharmaceutical Branch and Food Branch. Two new subsidiaries were established: Huangcheng Xiangfu Chain Pharmacy Subsidiary Company and Huangcheng Xiangfu Qinhe Pharmaceutical Co., Ltd.
Jilin Wutai Gankang Pharmaceutical Co., Ltd.
As the first brand of Wutai Group, "Guankang" entered the market in 1996 and has been sold for more than 20 years. Its sales volume has been at the forefront of domestic cold medicine products for many years. "Gankang" brand growth process: 1995: A decision that was of historic significance to Wutai Group - the acquisition of Jiangcheng Pharmaceutical Factory, Wutai Group entered the field of pharmaceutical industrialization. In the same year, the antiviral cold drug "Guankang" was developed and launched. "Gankang" has achieved great success with its accurate market positioning and marketing strategy. After it was put on the market, its brand value continued to rise and its reputation gradually expanded. 1998: In the Jilin Provincial Medical Market Census of Jilin Provincial Social Investigation Firm, "Guankang" was recognized as a high-quality representative product for cold resistance. 2015: Since 2015, the company has made drastic packaging reform and innovation. In 2016: The company developed a "pull-pull-type new packaging" and owned six patents. 2020: Gankang animation image is released for the first time.
Jilin Wutai Gankang Pharmaceutical Co., Ltd.
As the first brand of Wutai Group, "Guankang" entered the market in 1996 and has been sold for more than 20 years. Its sales volume has been at the forefront of domestic cold medicine products for many years. "Gankang" brand growth process: 1995: A decision that was of historic significance to Wutai Group - the acquisition of Jiangcheng Pharmaceutical Factory, Wutai Group entered the field of pharmaceutical industrialization. In the same year, the antiviral cold drug "Guankang" was developed and launched. "Gankang" has achieved great success with its accurate market positioning and marketing strategy. After it was put on the market, its brand value continued to rise and its reputation gradually expanded. 1998: In the Jilin Provincial Medical Market Census of Jilin Provincial Social Investigation Firm, "Guankang" was recognized as a high-quality representative product for cold resistance. 2015: Since 2015, the company has made drastic packaging reform and innovation. In 2016: The company developed a "pull-pull-type new packaging" and owned six patents. 2020: Gankang animation image is released for the first time.
Shandong Zibo Xinda Pharmaceutical Co., Ltd.
Shandong Zibo Xinda Pharmaceutical Co., Ltd. was established in 1993. It is a wholly-owned subsidiary of Shandong Xinhua Pharmaceutical Co., Ltd. and a high-tech enterprise integrating scientific research, production and service. Xinda Pharmaceuticals aims to "fresh and healthy, safe," and "update and shared with each other" as its business philosophy. It is committed to providing high-quality medicines and health services to the society. The company has R&D platforms such as provincial enterprise technology center, Zibo Diabetes Drug Engineering Technology R&D Center, etc., and has signed a cooperation agreement with Shandong University to establish a strategic alliance for technological innovation in major new drug creation industry, thereby continuously improving its own technical level. We now have a total of 32 valid knowledge patents, including 8 invention patents and 19 new drug certificates. It has 1 national first-class new drug and 3 national second-class new drug. The workshops have all passed the new version of GMP certification. At present, the company's products are oral solid preparations, with categories such as cephalosporins, penicillins, and ordinary; dosage forms are tablets, hard capsules, granules, and dry suspensions. The main product "Xindaro" (Cefacro) series products were introduced in China by the company in 1994. They have successively launched three dosage forms: capsules, granules, and sustained-release tablets. They are a famous domestic antibiotic brand for children and adults. Ranked among the top of similar varieties. "Chusing" is a cefuroxime dispersed tablet, which is the second generation of oral cephalosporin antibiotics. "Dunling" national new drug has a stable and long-lasting effect on lowering sugar, protecting the kidneys, and effectively reduces and improves cardiovascular complications. Looking to the future, Xinda Pharmaceutical is taking it as its mission to revitalize national medicine. With a high sense of social responsibility, through continuous technological innovation and a scientific, rigorous and responsible attitude, it will continue to provide safe, effective and economical medicines to the society. Dedicated to serve the health of all mankind.
Shandong Zibo Xinda Pharmaceutical Co., Ltd.
Shandong Zibo Xinda Pharmaceutical Co., Ltd. was established in 1993. It is a wholly-owned subsidiary of Shandong Xinhua Pharmaceutical Co., Ltd. and a high-tech enterprise integrating scientific research, production and service. Xinda Pharmaceuticals aims to "fresh and healthy, safe," and "update and shared with each other" as its business philosophy. It is committed to providing high-quality medicines and health services to the society. The company has R&D platforms such as provincial enterprise technology center, Zibo Diabetes Drug Engineering Technology R&D Center, etc., and has signed a cooperation agreement with Shandong University to establish a strategic alliance for technological innovation in major new drug creation industry, thereby continuously improving its own technical level. We now have a total of 32 valid knowledge patents, including 8 invention patents and 19 new drug certificates. It has 1 national first-class new drug and 3 national second-class new drug. The workshops have all passed the new version of GMP certification. At present, the company's products are oral solid preparations, with categories such as cephalosporins, penicillins, and ordinary; dosage forms are tablets, hard capsules, granules, and dry suspensions. The main product "Xindaro" (Cefacro) series products were introduced in China by the company in 1994. They have successively launched three dosage forms: capsules, granules, and sustained-release tablets. They are a famous domestic antibiotic brand for children and adults. Ranked among the top of similar varieties. "Chusing" is a cefuroxime dispersed tablet, which is the second generation of oral cephalosporin antibiotics. "Dunling" national new drug has a stable and long-lasting effect on lowering sugar, protecting the kidneys, and effectively reduces and improves cardiovascular complications. Looking to the future, Xinda Pharmaceutical is taking it as its mission to revitalize national medicine. With a high sense of social responsibility, through continuous technological innovation and a scientific, rigorous and responsible attitude, it will continue to provide safe, effective and economical medicines to the society. Dedicated to serve the health of all mankind.
Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group Co., Ltd. ( hereinafter referred to as "Habin Pharmaceutical Co., Ltd." ) is a large enterprise group integrating pharmaceutical manufacturing, trade and scientific research. In June 1993, the company was listed on the Shanghai Stock Exchange (stock code "600664"). The company covers three core business segments of industrial manufacturing, commerce and GNC. It has 10 industrial enterprises including Harbin Pharmaceutical Sanjing, Harbin Pharmaceutical General Factory, Harbin Pharmaceutical Six Factory, and Harbin Pharmaceutical Shiyitang. Harbin Pharmaceutical Renmin Tongtai (listed company ) and Harbin Pharmaceutical Marketing two commercial distribution companies, and also has a pharmaceutical research institute with strong scientific research capabilities, focusing on innovative research and development in high-tech fields such as central nervous system, anti-tumor, cardiovascular and cerebrovascular drugs. Hayao Co., Ltd. has 1,816 drug approvals and 74 health food approvals. The leading products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, prostadil injection, and pediatric aminophen yellow. Namin granules, Rasidipin tablets, ceftiam hydrochloride for injection, ibuprofen granules, Xingai Zhonggai brand high calcium tablets, etc. The company owns five trademarks: "Haya Medicine", "Three Essences", "Guizhong Gai", "Hutong" and "Shiyitang", with a brand value of more than 20 billion yuan. Integrity, professionalism, openness and inclusiveness, collaboration and responsibility, innovation and efficiency are the core values of corporate development. Harbin Pharmaceutical Co., Ltd. is an enterprise with relatively innovative capabilities and pioneering spirit. In the future, the company will coordinate the talent chain, industrial chain and capital chain, comprehensively build an open innovation ecosystem, constantly explore high-quality development paths, and continue to make efforts in many fields such as products, technology, R&D, intelligent manufacturing, business models, and management mechanisms. Breakthrough and transformation make Harbin Pharmaceutical a benchmark for Chinese national pharmaceutical companies that consumers, customers, employees and society are proud of.
Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group Co., Ltd. ( hereinafter referred to as "Habin Pharmaceutical Co., Ltd." ) is a large enterprise group integrating pharmaceutical manufacturing, trade and scientific research. In June 1993, the company was listed on the Shanghai Stock Exchange (stock code "600664"). The company covers three core business segments of industrial manufacturing, commerce and GNC. It has 10 industrial enterprises including Harbin Pharmaceutical Sanjing, Harbin Pharmaceutical General Factory, Harbin Pharmaceutical Six Factory, and Harbin Pharmaceutical Shiyitang. Harbin Pharmaceutical Renmin Tongtai (listed company ) and Harbin Pharmaceutical Marketing two commercial distribution companies, and also has a pharmaceutical research institute with strong scientific research capabilities, focusing on innovative research and development in high-tech fields such as central nervous system, anti-tumor, cardiovascular and cerebrovascular drugs. Hayao Co., Ltd. has 1,816 drug approvals and 74 health food approvals. The leading products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, prostadil injection, and pediatric aminophen yellow. Namin granules, Rasidipin tablets, ceftiam hydrochloride for injection, ibuprofen granules, Xingai Zhonggai brand high calcium tablets, etc. The company owns five trademarks: "Haya Medicine", "Three Essences", "Guizhong Gai", "Hutong" and "Shiyitang", with a brand value of more than 20 billion yuan. Integrity, professionalism, openness and inclusiveness, collaboration and responsibility, innovation and efficiency are the core values of corporate development. Harbin Pharmaceutical Co., Ltd. is an enterprise with relatively innovative capabilities and pioneering spirit. In the future, the company will coordinate the talent chain, industrial chain and capital chain, comprehensively build an open innovation ecosystem, constantly explore high-quality development paths, and continue to make efforts in many fields such as products, technology, R&D, intelligent manufacturing, business models, and management mechanisms. Breakthrough and transformation make Harbin Pharmaceutical a benchmark for Chinese national pharmaceutical companies that consumers, customers, employees and society are proud of.
Changchun Deeray Pharmaceutical Co., Ltd.
Xinganmine (compound aminophenol alkamine tablets) were launched by Changchun Dirui Pharmaceutical. Changchun Dirui Pharmaceutical Co., Ltd. was established in 2004 and is a national high-tech enterprise integrating pharmaceutical research and development, production and sales. Since its establishment, the company has developed rapidly and its comprehensive strength has been continuously improved. In recent years, it has obtained taxpayers with tax credit rating A grades, technology-based small and medium-sized enterprises, Jilin Province's "little giant" enterprise, and Changchun City's "specialized and specialized" Small and medium-sized enterprises, Changchun City's science and technology-based "little giant" enterprise, etc. The company is an enterprise in Jilin Province that has passed the on-site verification of the quality and efficacy consistency evaluation of generic drugs. Cephalexin capsules (0.25g) and acetaminophen tablets (0.5g) have passed the quality and efficacy consistency evaluation and obtained approval documents. The company covers an area of 27,162 square meters and has 10,671 square meters of GMP standard factory, including 2,174 square meters of standard warehouse, with five production workshops, including solid preparations, cephalosporin preparations, eye drops, liquid preparations and packaging. The production scope includes tablets ( Contains cephalosporins, hormones), hard capsules (including cephalosporins), granules, powders, eye drops, nose drops, ear drops, products cover entrapment, antibacterial, anti-inflammatory, antipyretic and analgesic , liver, gallbladder, gastrointestinal, cardiovascular and cerebrovascular, kidney and yang strengthening, vitamins, cough and relieve asthma, rheumatism, gynecology, pediatrics, etc., a total of 80 varieties and 102 documents. The company has 10 functional departments including sales, R&D, production, and quality. There are currently 240 employees and 76 employees above college degree. The high-quality management team leads employees to make steady progress towards the company's established goals. The company conscientiously implements the quality policy of "based on high-tech, pursuing quality, strengthening system control, and ensuring customer interests", and the product quality control system has been continuously improved and improved. In order to improve product quality, the company's R&D investment has increased year by year. Other eye drop varieties have been gradually selected for quality and efficacy consistency evaluation, so that the company's product quality can be further in line with international standards and the quality has reached a new level. Changchun Dirui Pharmaceutical Co., Ltd. takes "making fine medicines and creating healthy life" as its corporate philosophy, based on its own R&D advantages, constantly pursues high quality and high efficacy, and uses Dirui people's wisdom and innovation to contribute to the health cause of human beings. .
Changchun Deeray Pharmaceutical Co., Ltd.
Xinganmine (compound aminophenol alkamine tablets) were launched by Changchun Dirui Pharmaceutical. Changchun Dirui Pharmaceutical Co., Ltd. was established in 2004 and is a national high-tech enterprise integrating pharmaceutical research and development, production and sales. Since its establishment, the company has developed rapidly and its comprehensive strength has been continuously improved. In recent years, it has obtained taxpayers with tax credit rating A grades, technology-based small and medium-sized enterprises, Jilin Province's "little giant" enterprise, and Changchun City's "specialized and specialized" Small and medium-sized enterprises, Changchun City's science and technology-based "little giant" enterprise, etc. The company is an enterprise in Jilin Province that has passed the on-site verification of the quality and efficacy consistency evaluation of generic drugs. Cephalexin capsules (0.25g) and acetaminophen tablets (0.5g) have passed the quality and efficacy consistency evaluation and obtained approval documents. The company covers an area of 27,162 square meters and has 10,671 square meters of GMP standard factory, including 2,174 square meters of standard warehouse, with five production workshops, including solid preparations, cephalosporin preparations, eye drops, liquid preparations and packaging. The production scope includes tablets ( Contains cephalosporins, hormones), hard capsules (including cephalosporins), granules, powders, eye drops, nose drops, ear drops, products cover entrapment, antibacterial, anti-inflammatory, antipyretic and analgesic , liver, gallbladder, gastrointestinal, cardiovascular and cerebrovascular, kidney and yang strengthening, vitamins, cough and relieve asthma, rheumatism, gynecology, pediatrics, etc., a total of 80 varieties and 102 documents. The company has 10 functional departments including sales, R&D, production, and quality. There are currently 240 employees and 76 employees above college degree. The high-quality management team leads employees to make steady progress towards the company's established goals. The company conscientiously implements the quality policy of "based on high-tech, pursuing quality, strengthening system control, and ensuring customer interests", and the product quality control system has been continuously improved and improved. In order to improve product quality, the company's R&D investment has increased year by year. Other eye drop varieties have been gradually selected for quality and efficacy consistency evaluation, so that the company's product quality can be further in line with international standards and the quality has reached a new level. Changchun Dirui Pharmaceutical Co., Ltd. takes "making fine medicines and creating healthy life" as its corporate philosophy, based on its own R&D advantages, constantly pursues high quality and high efficacy, and uses Dirui people's wisdom and innovation to contribute to the health cause of human beings. .
Robitussin provides effective cough and cold remedies, including formulations for children.
Pfizer
Robitussin provides effective cough and cold remedies, including formulations for children.
Mucinex offers a range of cold and flu remedies, including pediatric formulations for cough and congestion.
Reckitt Benckiser
Mucinex offers a range of cold and flu remedies, including pediatric formulations for cough and congestion.
Motrin is another ibuprofen-based product line, including children's Motrin, for pain and fever relief.
Johnson & Johnson
Motrin is another ibuprofen-based product line, including children's Motrin, for pain and fever relief.
Advil offers a range of pain relief products, including children's Advil, known for its ibuprofen-based formulations.
Pfizer
Advil offers a range of pain relief products, including children's Advil, known for its ibuprofen-based formulations.
Alka-Seltzer is a well-known antacid and pain relief effervescent tablet brand, widely used for treating heartburn, indigestion, and headaches.
Bayer AG
Alka-Seltzer is a well-known antacid and pain relief effervescent tablet brand, widely used for treating heartburn, indigestion, and headaches.
Benadryl is a well-known brand for treating allergy symptoms, including nasal congestion and skin reactions. It is also used for its sedative effects in certain formulations.
Johnson & Johnson
Benadryl is a well-known brand for treating allergy symptoms, including nasal congestion and skin reactions. It is also used for its sedative effects in certain formulations.
Zyrtec is a leading antihistamine brand known for its effectiveness in treating allergies, including hay fever and hives. It offers both prescription and over-the-counter options.
Johnson & Johnson
Zyrtec is a leading antihistamine brand known for its effectiveness in treating allergies, including hay fever and hives. It offers both prescription and over-the-counter options.
Claritin is a popular antihistamine brand that provides relief from allergy symptoms such as sneezing, runny nose, and itchy eyes. It is widely recognized for its non-drowsy formula.
Bayer AG
Claritin is a popular antihistamine brand that provides relief from allergy symptoms such as sneezing, runny nose, and itchy eyes. It is widely recognized for its non-drowsy formula.
Siping Vickers Heat Exchange Equipment Co., Ltd.
China Siping Vickers Heat Exchange Equipment Co., Ltd. is a core member unit of Vickers International Group. It is currently one of the largest and most comprehensive professional manufacturing companies for heat exchange equipment in Asia. The design, manufacturing and R&D base of Vickers International Group is composed of branches with regional centers such as France, the United States, and Singapore, and its sales service network is spread all over the world. Integrating international advanced technology, Viex Group continues to innovate, and now ViEX has become a world-renowned manufacturer of heat exchange equipment. Over the past few decades, from Siping Heat Exchanger Factory to Siping Vickers Company, it has developed leap forward and bigger and stronger. The current garden-style factory covers an area of 60,000 square meters and has a construction area of 26,000 square meters. In 2004, after introducing the complete set of French fine molds and production processes, it has been continuously improved and optimized. Now we have 310 sets of various production, processing and inspection equipment. There are 460 fixed employees in the enterprise. Among them, scientific and technological personnel account for about 50% of the total number of employees. With the completion of the renovation of the old industrial base project in Northeast China, the company has expanded its production scale and capacity. Business scope Heat exchange equipment, environmental protection equipment and their edge products design, manufacturing, and sales; import and export of goods; import and export of technology and their agents. Corporate capabilities It produces 200,000 square meters and 4,000 sets (sets) of various heat exchange equipment annually. Annual sales of RMB 300 million, of which exports earn US$10 million.
Siping Vickers Heat Exchange Equipment Co., Ltd.
China Siping Vickers Heat Exchange Equipment Co., Ltd. is a core member unit of Vickers International Group. It is currently one of the largest and most comprehensive professional manufacturing companies for heat exchange equipment in Asia. The design, manufacturing and R&D base of Vickers International Group is composed of branches with regional centers such as France, the United States, and Singapore, and its sales service network is spread all over the world. Integrating international advanced technology, Viex Group continues to innovate, and now ViEX has become a world-renowned manufacturer of heat exchange equipment. Over the past few decades, from Siping Heat Exchanger Factory to Siping Vickers Company, it has developed leap forward and bigger and stronger. The current garden-style factory covers an area of 60,000 square meters and has a construction area of 26,000 square meters. In 2004, after introducing the complete set of French fine molds and production processes, it has been continuously improved and optimized. Now we have 310 sets of various production, processing and inspection equipment. There are 460 fixed employees in the enterprise. Among them, scientific and technological personnel account for about 50% of the total number of employees. With the completion of the renovation of the old industrial base project in Northeast China, the company has expanded its production scale and capacity. Business scope Heat exchange equipment, environmental protection equipment and their edge products design, manufacturing, and sales; import and export of goods; import and export of technology and their agents. Corporate capabilities It produces 200,000 square meters and 4,000 sets (sets) of various heat exchange equipment annually. Annual sales of RMB 300 million, of which exports earn US$10 million.
GlaxoSmithKline (China) Investment Co., Ltd.
Bili Pain is one of the painkillers that lead the world and is mainly composed of paracetamol. When everyone faces pain, only you can truly feel the feeling, and that is the important warning sent by your body to you. We sincerely share with you the knowledge and relief methods for dealing with daily pain, helping you to face various pain symptoms easily and make your loved ones more at ease. The Believer product series provides varying degrees of efficacy and is specially developed for children and colds to meet your needs.
GlaxoSmithKline (China) Investment Co., Ltd.
Bili Pain is one of the painkillers that lead the world and is mainly composed of paracetamol. When everyone faces pain, only you can truly feel the feeling, and that is the important warning sent by your body to you. We sincerely share with you the knowledge and relief methods for dealing with daily pain, helping you to face various pain symptoms easily and make your loved ones more at ease. The Believer product series provides varying degrees of efficacy and is specially developed for children and colds to meet your needs.
Cold-Eeze is a popular brand for cold symptom relief, utilizing zinc gluconate to reduce the duration and severity of colds.
ProPhase Labs
Cold-Eeze is a popular brand for cold symptom relief, utilizing zinc gluconate to reduce the duration and severity of colds.
